BioCentury
ARTICLE | Clinical News

Livatag doxorubicin Transdrug: Phase III started

May 21, 2012 7:00 AM UTC

BioAlliance began the open-label, international Phase III ReLive trial to evaluate 20 and 30 mg/m 2 IV Livatag in about 400 patients with HCC resistant or intolerant to sorafenib. Livatag has Orphan D...